MiR-148a, in addition to PD-L1, inhibits the human epidermal growth factor receptor 3 (HER3), Wnt/β-catenin pathway ligand—WNT10b, apoptosis regulator—BCL2, as well as VEGF and HIF1 in CRC; that is, it acts as a tumor suppressor [73,164,165,166,167]. The gene discussed is BCL2; the disease is neoplasm.